An Open Label Study to Establish the Preferred Dose and to Assess Safety and Overall Response Rate of Avastin in Combination With Concomitant Thoracic Radiation and Chemotherapy (Cisplatin and Etoposide) in Locally Advanced Unresectable Non-Squamous Non-Small Cell Lung Cancer.

Trial Profile

An Open Label Study to Establish the Preferred Dose and to Assess Safety and Overall Response Rate of Avastin in Combination With Concomitant Thoracic Radiation and Chemotherapy (Cisplatin and Etoposide) in Locally Advanced Unresectable Non-Squamous Non-Small Cell Lung Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 15 May 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Cisplatin; Etoposide
  • Indications Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 23 Feb 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 May 2009 Planned end date changed from 1 Oct 2010 to 1 Sep 2011 as reported by ClinicalTrials.gov.
    • 22 Oct 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top